Effect of Oncoxin, a Food Supplement, on Terminal-stage Hepatocellular Carcinoma Patients

Mamun Al Mahtab, S. M. Noor-E-Alam, Faysal Ahmed, D. C. Das
{"title":"Effect of Oncoxin, a Food Supplement, on Terminal-stage Hepatocellular Carcinoma Patients","authors":"Mamun Al Mahtab, S. M. Noor-E-Alam, Faysal Ahmed, D. C. Das","doi":"10.5005/jp-journals-10070-7061","DOIUrl":null,"url":null,"abstract":"Background: Liver cancer is currently the second-most common cause of cancer-related deaths worldwide and hepatocellular carcinoma (HCC) accounts for more than 90% of liver cancers. Patients with terminal HCC are those presenting with very poor Eastern Cooperative Oncology Group (ECOG) Performance Status 3–4 with tumors beyond the transplantation threshold. Their management of terminal HCC is only palliative support. Oncoxin is a nutritional supplement that is used as an over-the-counter nutritional prophylaxis for cancers. Our aim was to evaluate the effect of Oncoxin in terminal HCC patients along with the best supportive care (BSC), comparing that to the terminal-stage HCC patient only treated with BSC to determine the survival outcome as well as performance status, assessed by the ECOG Performance Status Scale. Materials and methods: This was a randomized control trial conducted at the Hepatology Department, Bangabandhu Sheikh Mujib Medical University (BSMMU) from December 2019 to February 2021. A total of 60 patients were included (30 patients for Oncoxin with BSC and 30 patients for BSC only) and randomized into two groups. They were followed up for 3 months. Results: In this study, it was observed that at 60 days, eight (26.7%) patients survived in the Oncoxin group and one (3.3%) patient survived in the BSC group. The difference was statistically significant ( p < 0.05). However, the Oncoxin administration had no survival benefit at 30 and 90 days follow up. After 30 days of treatment, a comparison of ECOG Performance Status between groups showed that all 12 (100%) patients in the Oncoxin group were in grade 3, while in the BSC group, four (44.4%) patients were in grade 3 and five (55.6%) patients were in grade 4. These differences were statistically significant. Conclusion: The study shows that Oncoxin appears to increase the survival of some, but not all, patients with terminal-stage HCC. The improvement of ECOG Performance Status was also observed.","PeriodicalId":207875,"journal":{"name":"Bengal Physician Journal","volume":"1 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bengal Physician Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5005/jp-journals-10070-7061","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Liver cancer is currently the second-most common cause of cancer-related deaths worldwide and hepatocellular carcinoma (HCC) accounts for more than 90% of liver cancers. Patients with terminal HCC are those presenting with very poor Eastern Cooperative Oncology Group (ECOG) Performance Status 3–4 with tumors beyond the transplantation threshold. Their management of terminal HCC is only palliative support. Oncoxin is a nutritional supplement that is used as an over-the-counter nutritional prophylaxis for cancers. Our aim was to evaluate the effect of Oncoxin in terminal HCC patients along with the best supportive care (BSC), comparing that to the terminal-stage HCC patient only treated with BSC to determine the survival outcome as well as performance status, assessed by the ECOG Performance Status Scale. Materials and methods: This was a randomized control trial conducted at the Hepatology Department, Bangabandhu Sheikh Mujib Medical University (BSMMU) from December 2019 to February 2021. A total of 60 patients were included (30 patients for Oncoxin with BSC and 30 patients for BSC only) and randomized into two groups. They were followed up for 3 months. Results: In this study, it was observed that at 60 days, eight (26.7%) patients survived in the Oncoxin group and one (3.3%) patient survived in the BSC group. The difference was statistically significant ( p < 0.05). However, the Oncoxin administration had no survival benefit at 30 and 90 days follow up. After 30 days of treatment, a comparison of ECOG Performance Status between groups showed that all 12 (100%) patients in the Oncoxin group were in grade 3, while in the BSC group, four (44.4%) patients were in grade 3 and five (55.6%) patients were in grade 4. These differences were statistically significant. Conclusion: The study shows that Oncoxin appears to increase the survival of some, but not all, patients with terminal-stage HCC. The improvement of ECOG Performance Status was also observed.
一种食物补充剂——致癌素对晚期肝细胞癌患者的影响
背景:肝癌目前是全球癌症相关死亡的第二大常见原因,肝细胞癌(HCC)占肝癌的90%以上。晚期HCC患者是那些表现为非常差的东部肿瘤合作组(ECOG)表现状态3-4且肿瘤超过移植阈值的患者。他们对晚期HCC的治疗仅仅是姑息性支持。致癌素是一种营养补充剂,被用作癌症的非处方营养预防药物。我们的目的是评估Oncoxin在终末期HCC患者中与最佳支持治疗(BSC)的效果,并将其与仅接受BSC治疗的终末期HCC患者进行比较,以确定生存结果以及通过ECOG表现状态量表评估的表现状态。材料和方法:这是一项随机对照试验,于2019年12月至2021年2月在Bangabandhu Sheikh Mujib医科大学(BSMMU)肝脏内科进行。共纳入60例患者(Oncoxin合并BSC患者30例,BSC患者30例),随机分为两组。随访3个月。结果:在本研究中,观察到60天时,Oncoxin组有8例(26.7%)患者存活,BSC组有1例(3.3%)患者存活。差异有统计学意义(p < 0.05)。然而,在30天和90天的随访中,给予Oncoxin没有生存获益。治疗30天后,组间ECOG表现状态比较显示,Oncoxin组12例(100%)患者均为3级,BSC组4例(44.4%)患者为3级,5例(55.6%)患者为4级。这些差异具有统计学意义。结论:研究表明,Oncoxin似乎增加了一些晚期HCC患者的生存,但不是全部。观察到ECOG性能状态的改善。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信